This study was performed to determine the haemodynamic effects of oral salbutamol and sublingual isosorbide dinitrate, alone and in
SUMMARY To examine possible augmentation of the effects of isosorbide dinitrate by salbutamol, haemodynamic measurements were made in 10 patients with severe chronic congestive cardiac failure who received isosorbide dinitrate 2-5 to 25 mg sublingually and salbutamol 4 to 12 mg orally, alone and in combination.
Isosorbide dinitrate reduced mean left ventricular filling pressure from 29 to 18 mmHg and increased mean cardiac index from 117 to 2-0 1/min per m2, with no significant change in mean heart rate. Systemic arterial mean pressure fell from 85 to 72 mmHg.
Salbutamol increased cardiac index from 1 8 to 2-2 1/min per M2. There was no significant change in left ventricular filling pressure, heart rate, or systemic arterial pressure.
Compared with control, combined isosorbide dinitrate and salbutamol reduced left ventricular filling pressure from 27 to 19 mmHg and increased cardiac index from 1-8 to 2-7 1/min per m2, with no significant change in heart rate. Systemic arterial pressure fell from 82 to 75 mmHg.
The reduction in left ventricular filling pressure by combined treatment was similar to that produced by isosorbide dinitrate alone, but the increase in cardiac index was After control measurements of heart rate, systemic arterial pressure, pulmonary arterial pressure, pulmonary artery wedge pressure (or pulmonary arterial end-diastolic pressure), and cardiac output, isosorbide dinitrate (Cedocard, Cedona, Holland) was administered sublingually in doses of between (Table 2) Effects of isosorbide dinitrate There was no significant change in mean heart rate. The mean value for systemic arterial mean pressure fell from 85 to 72mmHg (15%, p<001). The mean value for pulmonary arterial mean pressure fell from 37 to 24 mmHg (35%, p < 0 001), while that for pulmonary artery wedge mean pressure fell from 29 to 18 mmHg (38%, p < 0 001). Mean cardiac index increased from 1-7 to 2-0 1/min per m2 (18%, p < 0 01) and stroke volume index increased from 18 to 22 ml/m2 (22%, p < 0.01). There was no significant change in mean left ventricular stroke work index. Mean systemic vascular resistance fell from 2593 to 1777 dynes s cm-5 (31%, p < 0 001).
Effects of salbutamol There were no significant changes in mea'n values for heart rate or systemic arterial mean pressure. The mean value for pulmonary arterial mean pressure increased slightly from 35 to 37 mmHg (6%, p < 0.05) but there was no significant change in the mean value for pulmonary artery wedge mean pressure. Mean cardiac index increased from 1-8 to 2-2 I/min per m2 (22%, p < 0 001). An increase was observed in all patients, except one in whom no change could be effected despite the administration of 12 mg salbutamol (in this patient a large increase in cardiac index was observed when isosorbide dinitrate was administered concurrently) (Fig. 1) Fig. 4 Effects of isosorbide dinitrate (ISDN) and salbutamol, alone and in combination, on the relation between left ventricular filling pressure (L VFP) and cardiac index (CI). pressure may have been the result of a venoconstricting effect since adrenergic stimulation has been shown to produce venoconstriction in dogs,18 though a recent study in man'6 showed no effect of salbutamol on forearm venous tone.
In distinct contrast the principal effect of isosorbide dinitrate was to reduce left ventricular filling pressure. The observed haemodynamic effects of combined salbutamol and isosorbide dinitrate fulfilled the expectation of an additive effect in that there was a more comprehensive improvement in left ventricular performance than that produced by either agent alone (Fig. 4) . This improvement was achieved without serious hypotension, tachycardia, or arrhythmias.
Oral salbutamol and sublingual isosorbide dinitrate appear to have a beneficial, additive effect in patients with severe, chronic congestive cardiac failure. Though the haemodynamic results of this study relate to the acute effects of such a combination they appear to establish this as a possible new therapeutic approach in the long-term management of such patients.
